[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].

View at publisher Summarise with VIRAT
Authors: Masaki Maruta, Kento Mori, Koji Oka, Yuya Masuda, Junichi Kato, Tatsuya Konishi, Shogo Nabe, Yukihiro Miyazaki, Toshiki Ochi, Jun Yamanouchi, Katsuto Takenaka
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We report two cases of polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg-IFN) in which hematologic control was maintained without therapy after treatment discontinuation. The patients achieved complete response (CR) at 14 and 22 weeks after treatment initiation, respectively. After discontinuation of ropeg-IFN, Patient 1 has maintained hematocrit (Ht)

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Platelet Disorders and Treatments Hematological disorders and diagnostics

Publication details

Journal / source
PubMed
Volume
67
Issue
3
Pages
205–208
Publication date
1 January 2026
Language
JA